Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in
the Western world with limited therapeutic options and dismal long-term survival. The …

The tumor microenvironment (TME) is emerging as one of the primary barriers in cancer
therapy. Cancer-associated fibroblasts (CAF) are a common inhabitant of the TME in several …

Cancer-associated fibroblast (CAF) heterogeneity is increasingly appreciated, but the
origins and functions of distinct CAF subtypes remain poorly understood. The abundant and …

Pancreatic ductal adenocarcinoma (PDA) has one of the worst outcomes among all cancers,
with a median survival of∼ 6 mo and a 5-yr survival rate of< 8%(Siegel et al., 2016). Patients …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Cancer-associated fibroblasts (CAFs) are one of the most significant components in the
tumour microenvironment (TME), where they can perform several protumourigenic functions …

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in
humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment …

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

Pancreatic ductal adenocarcinoma (PDAC) has an extraordinarily dense fibrotic stroma that
impedes tumor perfusion and delivery of anticancer drugs. Since the extracellular matrix …